缩醛磷脂在阿尔茨海默病中的研究进展

金伊楠 ,  李文静 ,  边丽华 ,  郭建友

中国临床药理学与治疗学 ›› 2026, Vol. 31 ›› Issue (9) : 1256 -1264.

PDF (1599KB)
中国临床药理学与治疗学 ›› 2026, Vol. 31 ›› Issue (9) : 1256 -1264. DOI: 10.12092/j.issn.1009-2501.2026.09.012
综述与讲座

缩醛磷脂在阿尔茨海默病中的研究进展

作者信息 +

Research progress of plasmalogen in Alzheimer's disease

Author information +
文章历史 +
PDF (1636K)

摘要

阿尔茨海默病(Alzheimer's disease,AD)是一种进行性神经退行性疾病,其发病机制复杂,且目前治疗手段有限,亟需新的干预靶点。缩醛磷脂(plasmalogen)作为一种天然甘油磷脂,广泛存在于细胞膜(如髓鞘)和某些食物(如海鲜)中,其不仅具有显著的抗炎与抗氧化活性,还被证实参与记忆改善。越来越多的证据表明,缩醛磷脂的减少与 AD 的发生与发展密切相关。缩醛磷脂能够靶向多种关键机制干预 AD 的病理过程,包括清除 β-淀粉样蛋白(β-amyloid,Aβ)沉积、抑制细胞凋亡、促进神经发生和减少小胶质细胞的过度激活,从而发挥神经保护作用。因此补充缩醛磷脂有望成为一种防治 AD 的新策略。本文旨在总结并探讨缩醛磷脂在 AD 发病机制与治疗干预中的最新研究进展,以期为 AD 进一步研究和治疗提供新的方向。

Abstract

Alzheimer's disease (AD) is a progressive neurodegenerative disorder with complex pathogenesis and limited current treatment options, urgently requiring new intervention targets. Plasmalogen, a naturally occurring glycerophospholipid, is widely distributed in cell membranes (such as myelin sheaths) and certain foods (such as seafood). Not only do they exhibit significant anti-inflammatory and antioxidant activities, but they have also been demonstrated to participate in memory enhancement. Growing evidence indicates that reduced plasmalogens levels are closely associated with the onset and progression of AD. Plasmalogens can target multiple key mechanisms to intervene in AD pathological processes, including clearing amyloid-β (Aβ) deposits, inhibiting apoptosis, promoting neurogenesis, and reducing excessive activation of microglia, thereby exerting neuroprotective effects. Therefore, supplementing with plasmalogens holds promise as a novel strategy for preventing and treating AD. This article aims to summarize and explore the latest research advances on plasmalogens in AD pathogenesis and therapeutic interventions, with the goal of providing new directions for further AD research and treatment.

关键词

阿尔茨海默病 / 小胶质细胞 / 缩醛磷脂 / 脂质

Key words

Alzheimer's disease / microglia / plasmalogens / lipid

引用本文

引用格式 ▾
金伊楠,李文静,边丽华,郭建友. 缩醛磷脂在阿尔茨海默病中的研究进展[J]. 中国临床药理学与治疗学, 2026, 31(9): 1256-1264 DOI:10.12092/j.issn.1009-2501.2026.09.012

登录浏览全文

4963

注册一个新账户 忘记密码

参考文献

[1]

Scheltens P, De Strooper B, Kivipelto M,et al. Alzheimer's disease[J].Lancet, 2021, 397(10284): 1577-1590.

[2]

Hetz C, Martinon F, Rodriguez D, et al. The unfolded protein response: integrating stress signals through the stress sensor IRE1α[J].Physiol Rev, 2011, 91(4): 1219-1243.

[3]

Swerdlow RH, Burns JM, Khan SM. The Alzheimer's disease mitochondrial cascade hypothesis: progress and perspectives[J].Biochim Biophys Acta, 2014, 1842(8): 1219-1231.

[4]

Hashimoto S, Saido TC. Critical review: involvement of endoplasmic reticulum stress in the aetiology of Alzheimer's disease[J].Open Biol, 2018, 8(4): 180024.

[5]

Huang Z, Jordan JD, Zhang Q.Myelin pathology in Alzheimer's disease: potential therapeutic opportunities[J].Aging Dis, 2024, 15(2): 698-713.

[6]

Alzheimer's disease facts and figures[J].Alzheimers Dement, 2023, 19(4): 1598-1695.

[7]

Yin F. Lipid metabolism and Alzheimer's disease: clinical evidence, mechanistic link and therapeutic promise[J].FEBS J, 2023, 290(6): 1420-1453.

[8]

Honsho M, Yagita Y, Kinoshita N, et al. Isolation and characterization of mutant animal cell line defective in alkyl-dihydroxyacetonephosphate synthase: localization and transport of plasmalogens to post-Golgi compartments[J].Biochim Biophys Acta, 2008, 1783(10): 1857-1865.

[9]

Nagan N, Zoeller RA. Plasmalogens: biosynthesis and functions[J].Prog Lipid Res, 2001, 40(3): 199-229.

[10]

Braverman NE, Moser AB. Functions of plasmalogen lipids in health and disease[J].Biochim Biophys Acta, 2012, 1822(9): 1442-1452.

[11]

Rog T, Koivuniemi A. The biophysical properties of ethanolamine plasmalogens revealed by atomistic molecular dynamics simulations[J].Biochim Biophys Acta, 2016, 1858(1): 97-103.

[12]

Dorninger F, König T, Scholze P, et al. Disturbed neurotransmitter homeostasis in ether lipid deficiency[J].Hum Mol Genet, 2019, 28(12): 2046-2061.

[13]

Leßig J, Fuchs B. Plasmalogens in biological systems: their role in oxidative processes in biological membranes, their contribution to pathological processes and aging and plasmalogen analysis[J].Curr Med Chem, 2009, 16(16): 2021-2041.

[14]

Sambra V, Echeverria F, Valenzuela A, et al. Docosahexaenoic and arachidonic acids as neuroprotective nutrients throughout the life cycle[J].Nutrients, 2021, 13(3): 986.

[15]

Chen C, Liao J, Xia Y, et al. Gut microbiota regulate Alzheimer's disease pathologies and cognitive disorders via PUFA-associated neuroinflammation[J].Gut, 2022, 71(11): 2233-2252.

[16]

Liu ZG, Hualin W, Limei W, et al. Advances in research on neuron-protective role of polyunsaturated fatty acids[J].Food Sci, 2016, 37: 7: 239.

[17]

Jan AT, Azam M, Rahman S, et al. Perspective insights into disease progression, diagnostics, and therapeutic approaches in Alzheimer's disease: a judicious update[J].Front Aging Neurosci, 2017, 9: 356.

[18]

Breijyeh Z, Karaman R.Comprehensive review on Alzheimer's disease: causes and treatment[J].Molecules, 2020, 25(24): 5789.

[19]

Cras P, Kawai M, Lowery D, et al. Senile plaque neurites in Alzheimer disease accumulate amyloid precursor protein[J].Proc Natl Acad Sci U S A, 1991, 88(17): 7552-7556.

[20]

Armstrong RA. The molecular biology of senile plaques and neurofibrillary tangles in Alzheimer's disease[J].Folia Neuropathol, 2009, 47(4): 289-299.

[21]

Chen GF, Xu TH, Yan Y, et al. Amyloid beta: structure, biology and structure-based therapeutic development[J].Acta Pharmacol Sin, 2017, 38(9): 1205-1235.

[22]

Tabaton M, Piccini A.Role of water-soluble amyloid-beta in the pathogenesis of Alzheimer's disease[J].Int J Exp Pathol, 2005, 86(3): 139-145.

[23]

Metaxas A, Kempf SJ. Neurofibrillary tangles in Alzheimer's disease: elucidation of the molecular mechanism by immunohistochemistry and tau protein phospho-proteomics[J].Neural Regen Res, 2016, 11(10): 1579-1581.

[24]

Trejo-Lopez JA, Yachnis AT, Prokop S. Neuropathology of Alzheimer's disease[J].Neurotherapeutics, 2022, 19(1): 173-185.

[25]

Overk CR, Masliah E.Pathogenesis of synaptic degeneration in Alzheimer's disease and Lewy body disease[J].Biochem Pharmacol, 2014, 88(4): 508-516.

[26]

Koch G, Spampinato D.Alzheimer disease and neuroplasticity[J].Handb Clin Neurol, 2022, 184: 473-479.

[27]

Rajendran K, Krishnan UM.Biomarkers in Alzheimer's disease[J].Clin Chim Acta, 2024, 562: 119857.

[28]

王刚, 齐金蕾, 刘馨雅, 等. 中国阿尔茨海默病报告 2024[J].诊断学理论与实践, 2024, 23(3): 219-256.

[29]

Ginsberg L, Rafique S, Xuereb JH, et al. Disease and anatomic specificity of ethanolamine plasmalogen deficiency in Alzheimer's disease brain[J].Brain Res, 1995, 698(1-2): 223-226.

[30]

Han X, Holtzman DM, McKeel DW.Plasmalogen deficiency in early Alzheimer's disease subjects and in animal models: molecular characterization using electrospray ionization mass spectrometry[J].J Neurochem, 2001, 77(4): 1168-1180.

[31]

Goodenowe DB, Cook LL, Liu J, et al. Peripheral ethanolamine plasmalogen deficiency: a logical causative factor in Alzheimer's disease and dementia[J].J Lipid Res, 2007, 48(11): 2485-2498.

[32]

Yamashita S, Kiko T, Fujiwara H, et al. Alterations in the levels of amyloid-β, phospholipid hydroperoxide, and plasmalogen in the blood of patients with Alzheimer's disease: Possible interactions between amyloid-β and these lipids[J].J Alzheimers Dis, 2016, 50(2): 527-537.

[33]

Wood PL, Barnette BL, Kaye JA, et al. Non-targeted lipidomics of CSF and frontal cortex grey and white matter in control, mild cognitive impairment, and Alzheimer's disease subjects[J].Acta Neuropsychiatr, 2015, 27(5): 270-278.

[34]

Azad AK, Sheikh AM, Haque MA, et al. Time-dependent analysis of plasmalogens in the hippocampus of an Alzheimer's disease mouse model: a role of ethanolamine plasmalogen[J].Brain Sci, 2021, 11(12): 1603.

[35]

Dorninger F, Gundacker A, Zeitler G, et al. Ether lipid deficiency in mice produces a complex behavioral phenotype mimicking aspects of human psychiatric disorders[J].Int J Mol Sci, 2019, 20(16): 3929.

[36]

Hossain MS, Mawatari S, Fujino T.Plasmalogens, the vinyl ether-linked glycerophospholipids, enhance learning and memory by regulating brain-derived neurotrophic factor[J].Front Cell Dev Biol, 2022, 10: 828282.

[37]

Lee BY, Attwood SJ, Turnbull S, et al. Effect of varying concentrations of docosahexaenoic acid on amyloid beta (1-42) aggregation: an atomic force microscopy study[J].Molecules, 2018, 23(12): 3089.

[38]

Grimm MOW, Kuchenbecker J, Rothhaar TL, et al. Plasmalogen synthesis is regulated via alkyl-dihydroxyacetonephosphate-synthase by amyloid precursor protein processing and is affected in Alzheimer's disease[J].J Neurochem, 2011, 116(5): 916-925.

[39]

Rothhaar TL, Grösgen S, Haupenthal VJ, et al. Plasmalogens inhibit APP processing by directly affecting γ-secretase activity in Alzheimer's disease[J].ScientificWorldJournal, 2012, 2012: 141240.

[40]

Kou J, Kovacs GG, Höftberger R, et al. Peroxisomal alterations in Alzheimer's disease[J].Acta Neuropathol, 2011, 122(3): 271-283.

[41]

Katafuchi T, Ifuku M, Mawatari S, et al. Effects of plasmalogens on systemic lipopolysaccharide-induced glial activation and β-amyloid accumulation in adult mice[J].Ann N Y Acad Sci, 2012, 1262: 85-92.

[42]

Hossain MS, Tajima A, Kotoura S, et al. Oral ingestion of plasmalogens can attenuate the LPS-induced memory loss and microglial activation[J].Biochem Biophys Res Commun, 2018, 496(4): 1033-1039.

[43]

Li R, Xiong W, Li B, et al. Plasmalogen improves memory function by regulating neurogenesis in a mouse model of Alzheimer's diseases[J].Int J Mol Sci, 2023, 24(15): 12234.

[44]

Hossain MS, Ifuku M, Take S, et al. Plasmalogens rescue neuronal cell death through an activation of AKT and ERK survival signaling[J].PLoS One, 2013, 8(12): e83508.

[45]

Che H, Li Q, Zhang T, et al. A comparative study of EPA-enriched ethanolamine plasmalogen and EPA-enriched phosphatidylethanolamine on Aβ42 induced cognitive deficiency in a rat model of Alzheimer's disease[J].Food Funct, 2018, 9(5): 3008-3017.

[46]

Abdou HM, Hamaad FA, Elmageed GMA, et al. Efficacy of plasmalogens on monosodium glutamate-induced neurotoxicity in male rats through NF-κB and p38 MAPK signaling pathways[J].Oxid Med Cell Longev, 2025, 2025: 3673280.

[47]

Liu Y, Cong P, Zhang T, et al. Plasmalogen attenuates the development of hepatic steatosis and cognitive deficit through mechanism involving p75NTR inhibition[J].Redox Biol, 2021, 43: 102002.

[48]

Yu J, Su J, Zhang Y, et al. Mitigating effects of plasmalogens on age-related cognitive impairment[J].J Funct Foods, 2025, 128: 106790.

[49]

Bestard Escalas J. Role of membrane lipids in colon differentiation unravelled by mass spectrometry imaging: Arachidonic acid beyond inflammation[D]. Palma: Universitat de les Illes Balears,2019.

[50]

Amemori T, Jendelova P, Ruzicka J, et al. Alzheimer's disease: mechanism and approach to cell therapy[J].Int J Mol Sci, 2015, 16(11): 26417-26451.

[51]

Shirokov A, Zlatogosrkaya D, Adushkina V, et al. Plasmalogens improve lymphatic clearance of amyloid beta from mouse brain and cognitive functions[J].Int J Mol Sci, 2024, 25(23): 12552.

[52]

Takekoshi H, Fujishima M, Miyazawa T, et al. Simultaneous intake of chlorella and ascidian ethanolamine plasmalogen accelerates activation of BDNF-TrkB-CREB signaling in rats[J].Molecules, 2024, 29(2): 357.

[53]

Ifuku M, Katafuchi T, Mawatari S, et al. Anti-inflammatory/anti-amyloidogenic effects of plasmalogens in lipopolysaccharide-induced neuroinflammation in adult mice[J].J Neuroinflammation, 2012, 9: 197.

[54]

Hossain MS, Abe Y, Ali F, et al. Reduction of ether-type glycerophospholipids, plasmalogens, by NF-κB signal leading to microglial activation[J].J Neurosci, 2017, 37(15): 4074-4092.

[55]

Tremblay MÈ, Almsherqi ZA, Deng Y.Plasmalogens and platelet-activating factor roles in chronic inflammatory diseases[J].Biofactors, 2022, 48(6): 1203-1216.

[56]

Yamagiwa N, Kobayashi H, Okabayashi H, et al. Phosphatidylcholine-plasmalogen-oleic acid has protective effects against arachidonic acid-induced cytotoxicity[J].Biol Pharm Bull, 2022, 45(5): 643-648.

[57]

Gu J, Chen L, Sun R, et al. Plasmalogens eliminate aging-associated synaptic defects and microglia-mediated neuroinflammation in mice[J].Front Mol Biosci, 2022, 9: 815320.

[58]

Fujino T, Hossain MS, Mawatari S.Therapeutic efficacy of plasmalogens for Alzheimer's disease, mild cognitive impairment, and Parkinson’s disease in conjunction with a new hypothesis for the etiology of Alzheimer's disease[J].Adv Exp Med Biol, 2020, 1299: 195-212.

[59]

Hossain MS, Mineno K, Katafuchi T.Neuronal orphan G-protein coupled receptor proteins mediate plasmalogens-induced activation of ERK and Akt signaling[J].PLoS One, 2016, 11(3): e0150846.

[60]

Fujino M, Fukuda J, Isogai H, et al. Orally administered plasmalogens alleviate negative mood states and enhance mental concentration: a randomized, double-blind, placebo-controlled trial[J].Front Cell Dev Biol, 2022, 10: 894734.

[61]

Smith T, Knudsen KJ, Ritchie SA.A novel inducible animal model for studying chronic plasmalogen deficiency associated with Alzheimer's disease[J].Brain Res, 2024, 1843: 149132.

[62]

Hossain MS, Mawatari S, Honsho M, et al. KIT-13, a novel plasmalogen derivative, attenuates neuroinflammation and amplifies cognition[J].Front Cell Dev Biol, 2024, 12: 1443536.

[63]

Fujino T, Yamada T, Asada T, et al. Efficacy and blood plasmalogen changes by oral administration of plasmalogen in patients with mild Alzheimer's disease and mild cognitive impairment: a multicenter, randomized, double-blind, placebo-controlled trial[J].EBioMedicine, 2017, 17: 199-205.

[64]

Meletis CD. Alkyl-acylglycerols and the important clinical ramifications of raising plasmalogens in dementia and Alzheimer's disease[J].Integr Med (Encinitas), 2020, 19(3): 12-16.

[65]

Ouma S, Tsuboi Y, Mawatari S, et al. Effectiveness of blood plasmalogen in differentiation among mild cognitive impairment, mild Alzheimer's disease and normal elderly[J].J Neurol Sci, 2017, 381: 770.

[66]

Bergstrom S, Blomstrand R. The intestinal absorption and metabolism of chimyl alcohol in the rat[J].Acta Physiol Scand, 1956, 38(2): 166-172.

[67]

Brites P, Ferreira AS, da Silva TF, et al. Alkyl-glycerol rescues plasmalogen levels and pathology of ether-phospholipid deficient mice[J].PLoS One, 2011, 6(12): e28539.

[68]

Hoffman-Kuczynski B, Reo NV. Administration of myo-inositol plus ethanolamine elevates phosphatidylethanolamine plasmalogen in the rat cerebellum[J].Neurochem Res, 2005, 30(1): 47-60.

基金资助

北京自然科学基金(7254474)

浙江省智能教育技术与应用重点实验室开放研究基金(jykf22001w)

中科院心理所自主部署科研类项目(E4CX0915CX)

AI Summary AI Mindmap
PDF (1599KB)

0

访问

0

被引

详细

导航
相关文章

AI思维导图

/

〈 〉